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Introduction
IKAROS family transcription factors have been identified as key players in lym-
phopoiesis.1-5 Alterations of IKZF1 in acute lymphoblastic leukemia (ALL) were first
described in isolated cases in the early 1990s6,7 but it took several years to recognize
the important role of IKZF1 in ALL development.8,9 The crucial role of IKZF1 in ALL
development has also recently been underlined by the finding that certain non-cod-
ing single nucleotide polymorphisms in IKZF1 predispose to B lineage ALL devel-
opment in later life.10-12
The first larger studies on the incidence and role of IKZF1 alterations in ALL were
exclusively conducted on pediatric patients and revealed a prevalence of 15-30% of
Genetic alterations of the transcription factor IKZF1 ("IKAROS")are detected in around 15-30% of cases of BCR-ABL-negative B-cell precursor acute lymphoblastic leukemia. Different types of
intragenic deletions have been observed, resulting in a functionally inac-
tivated allele ("loss-of-function") or in "dominant-negative" isoforms.
The prognostic impact of these alterations especially in adult acute lym-
phoblastic leukemia is not well defined. We analyzed 482 well-character-
ized cases of adult BCR-ABL-negative B-precursor acute lymphoblastic
leukemia uniformly treated in the framework of the GMALL studies and
detected IKZF1 alterations in 128 cases (27%). In 20%, the IKZF1 alter-
ation was present in a large fraction of leukemic cells ("high deletion
load") while in 7% it was detected only in small subclones ("low deletion
load"). Some patients showed more than one IKZF1 alteration (8%).
Patients exhibiting a loss-of-function isoform with high deletion load
had a shorter overall survival (OS at 5 years 28% vs. 59%; P<0.0001), also
significant in a subgroup analysis of standard risk patients according to
GMALL classification (OS at 5 years 37% vs. 68%; P=0.0002). Low dele-
tion load or dominant-negative IKZF1 alterations had no prognostic
impact. The results thus suggest that there is a clear distinction between
loss-of-function and dominant-negative IKZF1 deletions. Affected
patients should thus be monitored for minimal residual disease carefully
to detect incipient relapses at an early stage and they are potential candi-
dates for alternative or intensified treatment regimes. (clinicaltrials.gov
identifiers: 00199056 and 00198991). 
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ABSTRACT
IKZF1 alterations in BCR-ABL-negative ALL3,9 compared
with a particularly large fraction in BCR-ABL-positive ALL
(more than 60%).8,13 IKZF1-alterated BCR-ABL-negative
pediatric ALL patients were reported to have an adverse
prognosis9,14-17 although this is still a subject of dispute.18
The negative prognostic effect was even found within
BCR-ABL-positive pediatric19 and adult13,20 patients.
In adult BCR-ABL-negative ALL patients, studies sug-
gested a worse outcome for IKZF1-mutated patients,
albeit there have been inconsistent results concerning the
prognostic impact of different IKZF1 alterations (Online
Supplementary Table S1).21-24 Furthermore, to the best of our
knowledge, the effect of multiple IKZF1 alterations or the
impact of mutation load25,26 has not been systematically
studied in this population.
The IKZF1 gene comprises eight exons, of which the
first  is non-coding. Its gene product is a 519 amino acid
protein with six zinc finger domains.4 The two carboxy-
terminal zinc fingers (exon 8) are responsible for dimeriza-
tion with other IKAROS family members.27 The four
amino-terminal zinc fingers (exons 4-6) mediate DNA
binding. Besides point mutations and the loss of the com-
plete IKZF1 gene, various intragenic types of deletions
have been experimentally observed. Loss of two or more
amino-terminal zinc fingers encoded by exons 4-6 with
deletion of the binding domain but retention of the dimer-
ization domain results in dominant-negative isoforms, i.e.
an isoform able to suppress the function of wild-type pro-
tein.27 Loss of exon 2 with the ATG start codon abolishes
gene transcription at all and loss of exon 8 removes the
dimerization domain. The latter two have historically
been called "haploinsufficient".3 Since this term implies
that the other allele is still functional, which could only be
proven with certainty by single cell analysis, we will use
the term "loss-of-function" for these alterations. 
In this study, we present an in-depth analysis of 482
BCR-ABL-negative patients with B-precursor ALL with
regard to their IKZF1 status. Patients were treated uni-
formly in the framework of the German Multicenter ALL
(GMALL) studies between 1999 and 2009. We present a
detailed genetic analysis and an assessment of the prog-
nostic impact of the various IKZF1 alterations.
Methods
Patients’ samples
Originally, 507 patients with BCR-ABL-negative B-cell precursor
(BCP) ALL were studied (Figure 1). Four were excluded because of
irreproducible results, and 21 for missing follow-up data (of these
only breakpoint sequences are presented).
Of the remaining 482 patients who were treated within the
GMALL protocols 06/99 (n=84; clinicaltrials.gov identifier: 00199056)
or 07/03 (n=398; clinicaltrials.gov identifier: 00198991), we analyzed
bone marrow (n=330) or peripheral blood with peripheral blasts
(n=132; bone marrow or peripheral blood not specified in n=20)
obtained at the time of diagnosis between 1999 and 2009 (for blast
count see Online Supplementary Tables S2 and S3).  Matched sam-
ples from the time of relapse were available for 16 out of 482
patients
GMALL studies
Detailed information on treatment has been published previ-
ously.28 The GMALL studies were approved by the ethics commit-
tee of the University of Frankfurt, Germany, and by local ethics
committees of participating institutions, and were conducted
according to the Declaration of Helsinki.
Immunophenotyping and molecular genetic analysis
At the time of diagnosis, immunophenotyping and molecular
genetic analysis were performed at the GMALL central laboratory
in Berlin, Germany. For all BCP-ALL patients, BCR-ABL status was
determined by RT-PCR. Other molecular targets (TCF3-PBX1,
ETV6-RUNX1 and MLL fusion genes) were analyzed according to
our diagnostic guidelines as outlined previously.29,30
Genomic PCR for Δ4-7, Δ2-7, Δ4-8, Δ2-8
For all patients, genomic PCR was performed using HotStarTaq
Polymerase Mastermix (QIAGEN) with 40-200 ng DNA and 500
nM of each primer under the following conditions: 15 minutes
(min) at 95°C, followed by 35 cycles of 30 seconds (sec) at 94°C,
30 sec at 65°C and 60 sec at 72°C. Primers were located in intron
1 (F2A ACTACAGAGACTTCAGCTCTATTCCATTTC, F2B
TGATTTGGATGTGTGTGTTTCATGCGTGG), intron 3 (F4
CTTAGAAGTCTGGAGTCTGTGAAGGTC), intron 7 (R7
AGGGACTCTCTAGACAAAATGGCAGGA) and 3’UTR of
IKZF1 (R8 CCTCCTGCTATTGCACGTCTCGGT). For primer
combinations see Online Supplementary Table S4. In all PCRs, a
fragment of intron 7 or 3'UTR was amplified as internal control
with primer concentration of 100 nM (F7 ACCATCAAAT-
ACAGGTCAACAGGACTGA, product 1,257 bp) or 50 nM (F8
CCCACTGCACAGATGAACAGAGCA, product 1,229 bp).
Primers were manufactured by metabion (Munich, Germany) or
TIB Molbiol (Berlin, Germany) and HPLC-purified. 
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Figure 1. Flowchart of the analysis.
Reverse transcriptase PCR
RT-PCR was performed with 2 µl cDNA, 500 nM of each
primer and the HotStarTaq Polymerase Mastermix (QIAGEN)
using the following conditions: 15 min at 95°C, followed by 35
cycles of 30 sec at 94°C, 30 sec at 64°C, and 60 sec at 72°C.
Primers were located in exons 1 and 8 (RT-PCR ex1/8, primers
ex1FA AAAGCGCGACGCACAAATCCA and ex8R
CGTTGTTGATGGCTTGGTCCATCAC) or in exon 1 and exon
4 for detection of Δ2-3 (RT-PCR ex1/4, primers ex1FB CGAG-
GATCAGTCTTGGCCCCAA and ex4R GAATGCCTC-
CAACTCCCGACAAAG). Long IKZF1 isoforms were used as
internal control. Bands of unexpected sizes were excised from the
gel and sequenced.
In cases where RNA was not available for RT-PCR, we used our
own and the PCR described by Meyer et al.31 as genomic screening
PCR.
Quantitative PCR for Δ4-7, Δ2-7, Δ4-8
Quantitative PCR was performed in duplicates either for all
patients (Δ4-7) or for patients positive in genomic PCR (Δ2-7 and
Δ4-8) using a Rotorgene 6000 cycler (Corbett, Concorde,
Australia), the Thermo Scientific ABsolute QPCR Mix (Life
Technologies, Darmstadt, Germany) with 200-250 ng DNA per
PCR and the following conditions: 15 min at 95°C, followed by 55
cycles for 15 sec at 95°C, and 60 sec at 60°C. 
As DNA standard, we used the cell-line BV-173 for Δ4-7
(DSMZ, Braunschweig, Germany)32 or patient DNA (#100 for Δ2-
7, #101 for Δ4-8). A PCR for the HCK gene served as internal con-
trol as described earlier.33 Oligonucleotides are given in Online
Supplementary Table S4.  Deletions were considered to be present
in a large fraction of leukemic cells ("high deletion load", "high-
del") when the relative PCR signal was >10-1, otherwise they were
considered having a "low deletion load" ("lowdel"). The cut-off
value was chosen a priori since this threshold appeared to separate
samples with a high and low mutation load (Online Supplementary
Figure S1). We used MLPA (SALSA MLPA P335 ALL-IKZF1 kit,
MRC Holland, Amsterdam, the Netherlands) to correlelate the
cut-off values of our quantitative PCRs with MLPA deletion val-
ues. We investigated a subset of patients with qPCR signals that
we expected to yield a MLPA reduction of 0.3 or more (i.e. qPCR
signal of 0.6 or higher). The chosen thresholds distinguishing high-
del and lowdel corresponded to 5% deleted alleles in case of Δ2-7
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Figure 2. Detection of IKZF1 deletions by RT-PCR and PCR screening. (A-C) RT-PCR ex1/8, PCR ∆4-7 and PCR ∆2-7 of the same 9 patients. (A) RT-PCR with primers
in exon 1/8. Increased Ik6 expression in lanes 4-6 and increased Ik10 expression in lanes 6-8. Reduced full length isoform expression in lanes 1 and 7 is attributed
to an additional deletion ∆2-3 in these 2 patients detected by another RT-PCR (see Online Supplementary Figure S2). (B) PCR ∆4-7. In lanes 1-3, ∆4-7 is present
with a low deletion load; in lanes 4-6, the deletion is present with a high deletion load. Corresponding qPCR results are given below. Control band of 1257bp. (C) PCR
∆2-7 with low deletion load in lanes 3-4 and high deletion load in lanes 6-8. Control band of 1257bp. (D) Structure of the IKZF1 transcript isoforms Ik1 (full-length),
Ik6 (loss of exons 4-7) and Ik10 (loss of exons 2-7). (E and F) PCR ∆4-8 and PCR ∆2-8 of the identical patients in lanes 10-17. Control band of 1229 bp. (E) PCR ∆4-







and Δ4-7, and 10% in Δ4-8, but the latter could equally well have
been placed at 5%, since there were no samples between 5% and
10%.
In cases negative for Δ4-7 by conventional PCR but positive by
qPCR, qPCR measurements were repeated and were considered
positive when at least 3 out of 4 measurements were positive.
Gel densitometry
When no quantification by qPCR was possible (n=41), we
assessed the relative amount of cells with IKZF1 deletions (high vs.
low deletion load) by gel band densitometry using the
AlphaEaseFC v.4.0 software (Alpha Innotech, San Leandro, CA,
USA). In deletions Δ2 (n=1) and Δ2-3 (n=17, missing values n=2),
we compared deleted isoforms to full-length isoforms on RT-PCR
images with a cut-off value of 0.60. In deletions Δ2-7 (n=5), Δ4-7
(n=3) and Δ5-7 (n=1) we compared deleted with long bands on
RT-PCR images using a cut-off value of 1.20. In Δ2-8 (n=10) and
Δ4-8 (n=2) we calculated the ratio of short PCR products to the
long PCR control band with a cut-off value of 1.20.
Supplementary methods
Nucleic acid preparation, identification of rare genomic break-
points (primer sequences specified in Online Supplementary Table
S5),31 DNA sequencing, bioinformatic analysis,34 and statistical
analysis are all described in the Online Supplementary Methods. 
Results
Patients’ characteristics
All 482 patients were aged between 16 and 65 years at
diagnosis (Online Supplementary Table S6). The median age
was 32 years [interquartile range (IQR) 22-47]. Two hun-
dred and eighty-five patients (59%) were male. The distri-
bution of immunophenotypes was 111 pre-B ALL (cyIg+;
23%), 314 common ALL (cyIg–,CD10+; 65%) and 57 pro-B
ALL (CD10–; 12%). Two hundred and fourteen patients
(44%) were considered high risk, the remaining standard
risk. All patients were BCR-ABL-negative and a MLL
rearrangement was detected in 44 patients (39 MLL-AF4,
4 MLL-ENL, 1 MLL-AF9), a TCF3-PBX1 fusion in 30, and
an ETV6-RUNX1 fusion in 3 cases.
Frequency of IKZF1 deletions
Two RT-PCRs were used to detect short IKZF1 isoforms
(Figure 2A and Online Supplementary Figure S2A-C) and
four separate PCRs to detect the Δ2-7, Δ2-8, Δ4-7 and 
Δ4-8 isoforms (Figure 2B-F). Deletions were then quanti-
fied using quantitative PCR or gel densitometry.
Dominant-negative deletions (Δ4-7, Δ5-7) were compared
to loss-of-function deletions (Δ2, Δ2-3, Δ2-7, Δ2-8, Δ4-8).
Overall, 128 of 482 (27%) patients carried an IKZF1
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Figure 3. Prevalence of IKZF1 deletions at the time
of diagnosis. (A) Frequency of all deletions as detect-
ed by PCR (∆2-7, ∆2-8, ∆4-7, ∆4-8) and RT-PCR (exon
1/4, exon 1/8). (B) Only deletions classified as high
deletion load by quantitative PCR and densitometry.
A
B
deletion (Figure 3A). Among these patients, we detected
175 different IKZF1 deletions. While 91 (19%) patients
expressed only one deletion, in 37 (8%) patients more
than one IKZF1 deletion was detected: 2 (n=28), 3 (n=8) or
4 (n=1) deletions (Online Supplementary Table S7; for an
example, see lanes 3, 4 and 6 in Figure 2).
Among the 175 IKZF1 deletions, Δ4-7 was the most fre-
quent  (n=71). Δ2-7 was found in 47, Δ4-8 in 26, Δ2-3 in 19
and Δ2-8 in 10 patients. Rare deletions were Δ5-7 (n=1)
and Δ2 (n=1). In summary, 56 patients (12%) carried only
loss-of-function deletions, 50 (10%) had only dominant-
negative deletions while 22 patients exhibited both types
of deletions (5%).
We then quantified the amount of cells with IKZF1
deletions, as a variable deletion load was apparent from
gel images (Figure 2B and C). We avoided the simple ter-
minology "clonal" and "subclonal" since we did not prove
clonality in a strict sense and did not investigate clonal
relationships. Instead, we adopted the terms "high dele-
tion load" (highdel) and "low deletion load" (lowdel) for
IKZF1 aberrations present either in the vast majority of
leukemic cells or only in a small fraction.
Out of 173 quantifiable deletions (n=2 not quantified),
106 (61%) were considered to have a high deletion load.
At least one highdel IKZF1 deletion could be found in 98
of 482 (20%) patients (Figure 3B). Among these, 50 had a
highdel loss-of-function deletion only, 44 patients had a
highdel dominant-negative deletion only, and there was a
group of 4 patients expressing both deletions with a high
deletion load level.
qPCR screening revealed 50 additional cases positive for
Δ4-7 with a low deletion load not detectable by our con-
ventional PCR. In 41 of these cases, the lowdel Δ4-7 was
the only IKZF1 deletion, while in 9 cases a loss-of-func-
tion deletion had been detected by conventional PCR.
Patients with a lowdel Δ4-7 detected by qPCR only were
considered IKZF1 wild-type.
Prognostic impact of IKZF1 deletions
Four hundred and twenty-eight (89%) patients reached
a complete remission, 31 patients (6%) died during induc-
tion, and 23 patients (5%) had a treatment failure after
induction. The overall survival was 55% at five years.
We first calculated the effect of any IKZF1 deletion
(n=128 vs. wild-type n=354) and then analyzed loss-of-
function (n=78 vs. negative n=404) and dominant-negative
deletions (n=72 vs. negative n=410) separately. We com-
pared the effect of high to low deletion load and no dele-
tion in the group of loss-of-function (n=54/23/404, miss-
ing value n=1) and dominant-negative deletions
(n=48/24/410).
There was a non-significant trend towards inferior over-
all survival (OS) for patients with any IKZF1 deletion (0.46
vs. 0.59; P=0.06) (Online Supplementary Figure S3A).
Patients carrying a loss-of-function IKZF1 deletion had a
reduced OS (0.37 vs. 0.59; P=0.0012) (Figure 4A) while
dominant-negative deletions had no effect on OS (0.54 vs.
0.56; P=0.95) (Figure 4B). Patients with both dominant-
negative and loss-of-function deletions showed a clinical
course comparable to loss-of-function deletions only
(Online Supplementary Figure S3B). Analysis of the amount
of IKZF1-deleted cells showed that the inferior survival in
loss-of-function deletions was an effect of highdel loss-of-
function deletions only (Figure 4C). Lowdel loss-of-func-
tion deletions did not influence the clinical course. In dom-
inant-negative deletions, OS was not associated with the
relative amount of IKZF1-deleted cells (Figure 4D).
Patients with highdel loss-of-function deletions showed
a reduced OS (0.28 vs. 0.59; P<0.0001) (Table 1). In sub-
groups according to risk stratification, highdel loss-of-
function IKZF1 deletions conferred a negative prognostic
effect on standard-risk patients (0.37 vs. 0.68; P=0.0002),
while in high-risk patients, the trend towards inferior OS
narrowly missed statistical significance (0.26 vs. 0.46;
P=0.06).
Clinico-biological characteristics of patients with
IKZF1 deletions
Patients with IKZF1 deletion showed a common
immunophenotype significantly more often than patients
without IKZF1 deletions (98 in 128, 77%, vs. 216 in 354,
61%; P=0.0064). The former were also significantly more
likely to be CD34-positive (112 in 127, 88%, vs. 209 of
353, 59%; P<0.0001; n=2 CD34 N/A). The occurence of
IKZF1 deletions was not associated with patients' age,
gender, WBC or GMALL risk group, neither for all dele-
tions (Online Supplementary Table S8) nor for different
types of deletion (Online Supplementary Table S9).
TCF3-PBX1 and IKZF1 deletions were mutually exclusive
(0 of 30 TCF3-PBX1+ vs. 64 of 250 TCF3-PBX1−; P=0.0004).
One in 3 ETV6-RUNX1-positive patients showed an IKZF1
deletion. There was a trend towards a lower frequency of
IKZF1 deletions in MLL-positive patients (7  of 44 MLL+,
16% vs. 7  of 26 MLL-, 26%; P=0.3556).
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Table 1. Effect of IKZF1 deletions on overall survival.
Type of IKZF1 Patient Cases Overall survival P
deletion group pos/neg positive negative
Any mutation all patients 128/354 0.46±0.05 0.59±0.03 ns (0.06)
Loss-of-function all patients 78/404 0.37±0.06 0.59±0.02 0.0012
Dominant-negative all patients 72/410 0.54±0.06 0.56±0.02 ns (0.95)
High deletion load loss-of-function all patients 54/427 0.28±0.06 0.59±0.02 <0.0001
SR 24/243 0.37±0.10 0.68±0.03 0.0002
HR 30/184 0.26±0.08 0.46±0.04 ns (0.06)
pos: positive; neg: negative; ns: not significant;  SR: standard risk according to the German Multicenter Acute Lymphoblastic Leukemia (GMALL) studies; HR: high risk accord-
ing to GMALL.
Oligoclonality is more common in loss-of-function 
deletions
Some patients showed more than one IKZF1 deletion
(e.g. Δ2-7 and Δ4-7). Forty out of 175 deletions (23%)
showed more than one chromosomal breakpoint resulting
in the same type of RNA transcript. This oligoclonality
may arise from multiple alterations in a single hyperdipoid
clone or from alterations in different clones. This was evi-
dent either by gel electrophoresis (9 patients; see lanes 9-
10 in Figure 2E and F) or by multiple sequences in chro-
matograms (2 breakpoints in 5 patients, Figure 5A; more
than two breakpoints in 26 patients, Figure 5B). This kind
of oligoclonal pattern occurred more often in loss-of-func-
tion deletions (31  of 103 deletions, 30%) compared with
dominant-negative (9 of 72, 13%; P=0.0064).
Breakpoint sequences
Sequencing of 193 breakpoints revealed four clusters
(Figure 5C; for all breakpoints see Online Supplementary
Table S10). In intron 1, 66 of 83 were located within 30bp.
In intron 3, 106  of 108 proximal breakpoints were located
within 40bp. All 132 distal breakpoints in intron 7 clus-
tered within 43bp. Thirty-six  of 42 breakpoints in the
3'UTR region were located in a 27bp region, and an addi-
tional 5 breakpoints clustered around 500bp proximally.
The remaining 17 breakpoints in intron 1 were more
diverse, covering a region of 7kb. Distal (3') breakpoints in
intron 3 (Δ2-3) were scattered all over the 40kb intron. In
183 of 193 (95%) molecularly characterized breakpoints,
putative cryptic recombination signal sequences, either
with 23bp or 12bp spacer, were identified at both break-
point sites (5' and 3'). This was the case for the four major
breakpoint clusters (Figure 5 and Online Supplementary
Table S11) but also true for the majority of the atypical
breakpoints in intron 1 and 3. In 10 of 25 atypical break-
points, only one cRSS could be identified (8 only on the 3'
site, 2 only on the 5' site) (Online Supplementary Table S11).
There was no evidence of somatic hypermutation near the
break sites.
Detection of deletions by RT-PCR
In 13 of 17 patients positive for Δ2-3 in RT-PCR ex1/4, a
genomic breakpoint could be identified by eyer et al.'s
PCR (Online Supplementary Figure S2A).31 In the remaining
4 patients, breakpoints were identified by a newly devel-
oped PCR (Online Supplementary Figure S2B). We also iden-
tified Δ2 once by RT-PCR ex1/4 and confirmed the
genomic deletion. One patient expressed isoform Δ2-4 in
RT-PCR ex1/8 but we could only find a deletion Δ2-3 on
the genomic level and no deletion Δ2-4 or Δ4.
RT-PCR revealed 3 patients positive for Ik10 (lacking
exons 2-7) but negative for Δ2-7 by genomic PCR due to a
more proximal 5' breakpoint (Online Supplementary Figure
S4A). In all 70 cases of RT-PCR positive for Ik6 (lacking
exons 4-7) and negative for Ik6Δ (lacking exons 4-7 but
with an additional 60 bp cryptic exon 3b),7,35 genomic PCR
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Figure 4. Overall survival (OS) depending on IKZF1 deletions. (A) OS of patients with loss-of-function IKZF1 deletions. (B) OS of patients with dominant-negative dele-









was positive for deletion Δ4-7. In one patient with Ik6 and
Ik6Δ we found two deletions Δ4-7, one with common
breakpoints, one with a 5' breakpoint distal to the 60bp
insert (Online Supplementary Figure S4B). The second
patient with Ik6/Ik6Δ showed only a deletion Δ5-7 that
was supposedly the reason for overexpression of Ik6 and
Ik6Δ (Online Supplementary Figure S4C).
Comparison between diagnosis and relapse
DNA at the time of relapse was available from 16
patients carrying 20 IKZF1 deletions. Four in 7 (57%) Δ4-
7 and 9 in 13 (69%) loss-of-function deletions were con-
served (P=0.65) (Online Supplementary Table S12). Eleven in
15 (73%) highdel and 1 in 4 lowdel deletions were con-
served (P=0.12; 1 deletion not quantified). All genomic
breakpoints were identical at the time of diagnosis and
relapse. No newly acquired deletion Δ2-7, Δ2-7, Δ4-7 or
Δ4-8 could be detected in relapse samples. We also inves-
tigated 5 relapse samples from patients who had shown a
lowdel Δ4-7 IKZF1 deletion at diagnosis, detectable only
by quantitative PCR. None of these cases evolved into a
major clone, i.e. with high deletion load at relapse.
Discussion
IKZF1 alterations have been recognized as recurrent
aberrations in B-precursor ALL but their prognostic impact
in adult ALL is still not well defined. Two major studies
involving more than 200 patients have focused on the
prognostic impact in BCR-ABL-negative adult BCP ALL.
Moorman et al.21 investigated 304 patients and found
IKZF1 deleted patients (29%) to have a lower OS, but this
was only seen in a univariate analysis. The authors stated
cautiously that "there was evidence to suggest that the
poor outcome was not linked to the expression of the IK6
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Figure 5. Distribution of IKZF1 breakpoints and clonality of deletions. (A) Chromatogram of patient #189 showing two distinguishable clones (sequenced sense and
antisense reverse complement). (B) Chromatogram of patient #395 showing oligoclonality at the breakpoint junction in both sequencing directions. (C) Distribution
of breakpoints in the IKZF1 gene locus. Proximal breakpoints are shown in black, distal breakpoints in blue. There are four major breakpoint clusters within intron
1, 3, 7 and 3’UTR of IKZF1. 
A B
C
isoform but rather to other types of IKZF1 deletions".21
Beldjord et al.22 investigated 216 younger adults and
observed a significantly higher cumulative incidence of
relapse in patients with focal IKZF1 alterations (25%) but
not with whole gene deletion. No statistically significant
difference between patients with different focal alter-
ations was observed.
Our present study included 482 homogenously treated
patients and revealed IKZF1 alterations in 128 cases. The
incidence of focal deletions (27%) was comparable to
both studies mentioned above. Our study is the first to
systematically address the issue of IKZF1 mutation load
and its implications for prognosis on a larger scale. This is
of diagnostic interest if IKZF1 alterations are to be used as
molecular markers for risk stratification and/or for detect-
ing minimal residual disease.15,26 Ninety-eight patients
revealed a high deletion load IKZF1 aberration while 29
patients showed low deletion load IKZF1 alterations only
(n=1 not quantified). Regarding clinical implications, only
high deletion load loss-of-function IKZF1 alterations were
of prognostic relevance and conferred an adverse progno-
sis while low deletion load IKZF1 alterations or dominant-
negative IKZF1 alterations did not have a prognostic
effect.
In animal studies, double IKZF1 knock-out mice show a
total absence of B cells.36 Mice with only IKZF1 deletions
did not develop BCP ALL, but haploinsufficiency of IKZF1
in BCR-ABL-transgenic mice significantly accelerated the
development of BCP ALL.37 Current evidence suggests
that IKZF1 alterations alone are not sufficient to cause
leukemia in humans but are an important co-factor or sec-
ondary event in the development and acceleration of ALL
disease. 
It may seem unexpected that the loss of one IKZF1 allele
without apparent functional alteration of the other allele
should have such a significant prognostic effect. However,
this is supported by the above mentioned mouse model of
Virely et al.37 The observation that loss-of-function IKZF1
deletions frequently occur in a small fraction of cells, but
only seem to have an impact on prognosis if they are
found in a large fraction, requires some explanation. A
hypothetical explanation is the assumption that RAG-
mediated IKZF1 deletions occur sporadically during all
stages of B-cell maturation because of the ongoing process
of VDJ recombination.38,39 However, only those IKZF1
aberrations occurring at a very early maturation stage are
thought to result in a cell phenotype with the full capacity
of self-renewal, i.e. a "leukemia stem cell phenotype".40
IKZF1 alterations occurring at later stages of B-cell matu-
ration should result in low deletion load aberrations.
The extremely narrow clustering of breakpoints in
regions comprising only a few nucleotides strongly argues
in favor of a specific mechanism. The analysis of the
breakpoint junctions revealed four breakpoint clusters in
the vicinity of recombination signal sequences suggestive
of a break mechanism involving the immunoglobulin VDJ
recombination enzyme complex. RAG1 and RAG2 and
other genes involved in VDJ rearrangement are not
expressed at a very early stage of differentiation but only
after lymphoid committment,41 which would be in line
with the assumption that IKZF1 deletions are a later event
in the path towards the malignant phenotype. The fact
that cRSS could not be identified in 10 out of 193 break-
points may be explained by limitations of the RSSsite soft-
ware, since some of these breaks occurred in near vicinity,
suggesting a specific mechanism. 
The PCR method used in this study has the advantage
that it can also detect IKZF1 alterations in a small fraction
of leukemic cells, which is not possible when using
MLPA.26 Since we analyzed the final IKZF1 cDNA tran-
script, we were in principle also able to detect deletions or
aberrant splice isoforms arising from alterations involving
only a few nucleotides that would escape detection by
MLPA. However, MLPA has the advantage of also detect-
ing whole gene deletions that are not detectable with our
PCR-based approach. As long as there are no reliable PCR-
based detection methods for the former, and given the fact
that low deletion load alterations are prognostically irrele-
vant, we consider MLPA to be a suitable detection
method.
To summarize, we detected partial IKZF1 gene dele-
tions in approximately 27% of cases of adult 
BCR-ABL-negative adult ALL. Only high deletion load
loss-of-function IKZF1 alterations, but not dominant-neg-
ative IKZF1 alterations, had negative prognostic implica-
tions and should thus be monitored closely, while those
that were found in a small fraction of cells did not influ-
ence prognosis. We report extensive molecular data on
these alterations which should help to establish suitable
diagnostic methods for their detection and which shed
additional light on the molecular pathogenesis.
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